Inherited thrombophilias: Implications for pregnancy-associated venous thromboembolism and obstetric complications

Current Problems in Obstetrics, Gynecology and Fertility

Volumn 24, Issue 4, 2001, Pages 109-149

  McLintock, C ^a   North, R A ^a   Dekker, G ^a   Taylor, R N ^a  

^a Diagnostic Medlab Ltd ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; HOMOCYSTEINE; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ANAMNESIS; ANTITHROMBIN DEFICIENCY; DNA POLYMORPHISM; FEMALE; FETUS WASTAGE; FIBRINOLYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY; PREVALENCE; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; SOLUTIO PLACENTAE; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS PREVENTION; TREATMENT PLANNING;

EID: 0034875128     PISSN: 87560410     EISSN: None     Source Type: Journal    
DOI: 10.1067/mog.2001.116890     Document Type: Review

References (272)

1. Inherited thrombophilia and adverse pregnancy outcome: Has the time come for selective testing?
2. The challenge of thrombophilia in maternal-fetal medicine
3. Thrombosis in pregnancy: Maternal and fetal issues
4. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy
5. Venous thrombosis: A multicausal disease
6. Antiphospholipid antibodies and thrombosis
7. Surface dependent reactions of the vitamin K-dependent enzyme complexes
8. The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets
9. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations
10. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
11. Biochemistry and physiology of blood coagulation
12. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells
13. The evaluation of complex-dependent alterations in human factor VIIa
14. Factor XI deficiency detection and management during urologic surgery
15. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin
16. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein
17. Stimulation of cyclin GMP production in cultured endothelial cells of the pig by bradykinin, adenosine phosphate, calcium ionophore A23187 and nitric oxide
18. Factor XI activation in a revised model of coagulation
19. Efficacy and safety of recombinant human activated protein C for severe sepsis
20. Regulation of coagulation by a multivalent Kunitz-type inhibitor
21. The 536C to T transition in the human tissue factor pathway inhibitor (TPFI) gene is statistically associated with a higher risk for venous thrombosis
22. Antithrombin: The principal inhibitor of thrombin
23. The protein C anticoagulant system: Inherited defects as a basis for venous thrombosis
24. The mechanism of inactivation of human factor V and human factor Va by activated protein C
25. Regulation of plasminogen activator production by endothelial cells: Role in fibrinolysis and local proteolysis
26. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
27. Mechanisms of physiological fibrinolysis
28. High levels of factor IX increase the risk of venous thrombosis
29. High levels of coagulation factor XI as a risk factor for venous thrombosis
30. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - A possible evolutionary selection mechanism
31. Use of a clinical model for safe management of patients with suspected pulmonary embolism
32. Non-invasive diagnosis of venous thromboembolism in outpatients
33. Increased fetal loss in women with heritable thrombophilia
34. Inherited antithrombin deficiency causing thrombophilia
35. Prevalence of antithrombin deficiency in the healthy population
36. Actions and interactions of antithrombin and heparin
37. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study)
38. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in out-patients with deep-venous thrombosis
39. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study
40. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the International Society on Thrombosis and Haemostasis
41. Prevalence of antithrombin III deficiency in blood donors selected for personal or familial history of venous thrombosis
42. Antithrombin III deficiency and thromboembolism
43. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S
44. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: A multicenter collaborative family study
45. Clinical manifestations and management of inherited thrombophilia: Retrospective analysis and follow-up after diagnoses of 238 patients with congenital deficiency of antithrombin III, protein C, protein S
46. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency
47. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C or protein S: A prospective study
48. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis
49. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome
50. Changes in plasma antithrombin (heparin cofactor activity) during intravenous heparin therapy: Observations in 198 patients with deep venous thrombosis
51. Deficiency of protein C in congenital thrombotic disease
52. Prevalence of protein C deficiency in the healthy population
53. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis
54. Molecular basis for protein C hereditary deficiency
55. Protein C deficiency: A database of mutations, 1995 update
56. Evolution and organisation of the human protein C gene
57. Activated protein C resistance caused by Arg506Gln mutation in factor Va
58. A molecular model of the serine protease domain of activated protein C: Application to the study of missense mutations causing protein C deficiency
59. Hereditary protein C deficiency: A review of the genetics, clinical presentation, diagnosis and treatment
60. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect
61. Changes in protein C and protein S levels in normal pregnancy
62. Venous thrombosis due to poor anticoagulant response to activated protein: Leiden Thrombophilia Study
63. Congenital thrombophilia among patients with venous thromboembolism
64. Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with a history of venous thrombosis and criteria for rational patient screening
65. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy
66. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
67. Mutation in blood coagulation factor V associated with resistance to activated protein C
68. Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor V
69. Identification of the same factor V gene mutation in 47 out of 50 thrombosisprone families with inherited resistance to activated protein C
70. 306 to Thr) associated with resistance to activated protein C
71. High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis
72. The population genetics of factor V Leiden (Arg506Gln)
73. The prevalence of Factor V Leiden (Gln 506) in Polynesians
74. Thrombosis in the young: Epidemiology and risk factors. A focus on venous thrombosis
75. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden
76. Activated protein C resistance (APC) and inherited factor V (FV) missense mutation in patients with venous and arterial thrombosis in a haematology clinic
77. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men
78. Risk of venous thromboembolism in asymptomatic family members with single identified factor V Leiden mutation: A prospective study
79. 506 to Gln mutation in the gene for factor V (factor V Leiden)
80. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V Leiden mutation with a first episode of deep-vein thrombosis
81. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism
82. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
83. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation
84. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
85. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency
86. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families?
87. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families
88. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism
89. Modified test for activated protein C resistance
90. Activated protein C resistance in normal pregnancy
91. Changes of resistance to activated protein C in the course of pregnancy and prevalence of factor V mutation
92. Development of resistance to activated protein C during pregnancy
93. Changes in activated protein C resistance during normal pregnancy
94. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
95. Endothelial cell metabolism and atherosclerosis
96. Total homocysteine in plasma or serum: Methods and clinical applications
97. Cobalamin-dependent methionine synthase
98. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
99. Intermediate homocysteinaemia: A thermolabile variant of methylenetetrahydrofolate reductase
100. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review
101. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations
102. A second mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects?
103. Homocysteine and atherothrombosis
104. An alternative view of homocysteine
105. Homocysteine and folate levels as risk factors for recurrent early pregnancy loss
106. Hyperhomocysteinemia and deep-vein thrombosis: A case-control study
107. Prevalence of moderate hyperhomocysteinemia in patients with early onset venous and arterial occlusive disease
108. High prevalence of hyperhomocyst(e)inaemia in patients with juvenile venous thrombosis
109. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis?
110. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
111. Plasma homocysteine in venous thromboembolism
112. Plasma homocysteine levels in patients with deep venous thrombosis
113. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506)
114. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-venous thrombosis
115. TL-MTHFR and venous thromboembolic disease
116. The VITA project: C677T mutation in the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism
117. A common mutation in methylenetetrahydrofolate reductase is associated with an increased risk of venous thrombosis
118. Prevalence of factor V 1691G to A and methylenetetrahydrofolate reductase 677C to T mutated genes in patients with venous thrombosis
119. The mutation Ala677 to Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis
120. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction
121. Total homocyst(e)ine in plasma and amniotic fluid of pregnant women
122. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
123. The prothrombin gene G20210A variant: Prevalence in a U.K. anticoagulant clinic population
124. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene
125. The incidence of venous thromboembolism in relatives of patients with the prothrombin 20210A mutation
126. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia
127. APC resistance and other hemostatic variables during pregnancy and puerperium
128. Allele-specific increases in basal transcription of the plasminogen-activator inhibitor I gene is associated with myocardial infarction
129. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia
130. Association of a common polymorphism in the factor XIII gene with venous thrombosis
131. Maternal mortality: Confidential enquiries into maternal deaths in the United Kingdom
132. Venous thromboembolism during pregnancy: A current review of diagnosis and management
133. Risk factors for venous thromboembolism in pregnancy
134. The special case of venous thromboembolism in pregnancy
135. Deep vein thrombosis during pregnancy and the puerperium: A meta-analysis of the period of risk and the leg of presentation
136. Venous thrombosis during pregnancy: Leg and trimester of presentation
137. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy
138. Venous thromboembolism in pregnancy and the puerperium: Incidence and additional risk factors from a London perinatal database
139. Prothrombin 20210 G→, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy
140. Risk factors for pregnancy associated venous thromboembolism
141. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium
142. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S: Study of 78 women
143. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S
144. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: Implications for prophylaxis
145. Pregnancy in women with thrombophilia: Incidence of thrombosis and pregnancy outcome
146. Risk of thrombosis during pregnancy and post-partum in hereditary thrombophilia
147. Resistance to activated protein C in healthy women taking oral contraceptives
148. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
149. Venous thrombosis during pregnancy: Prevalence of mutations in the genes for factor V (FV:R 506Q) and prothrombin (20210A)
150. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: Prevalence of factor V Leiden
151. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis
152. Arg506Gln mutation in factor V and risk of thrombosis during pregnancy
153. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy
154. Genetic factors associated with thrombosis in pregnancy in a United States population
155. Genetic susceptibility to pregnancy-related venous thromboembolism: Roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations
156. Prospective evaluation of the risk conferred by Factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy
157. Prevalence of factor V Leiden among patients with venous thrombosis, small deep infarction, antiphospholipid syndrome or venous thromboembolic complications in obstetrics and gynaecology
158. Activated protein C resistance (FV:Q506) and pregnancy
159. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group
160. Incidence of venous thromboembolism in families with inherited thrombophilia
161. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis
162. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in 85 women homozygous for factor V Leiden
163. Diagnostic problems with venous thromboembolic disease in pregnancy
164. Use of antithrombotic agents during pregnancy
165. Anticoagulation of pregnant women with mechanical heart valves
166. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
167. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
168. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
169. Low molecular weight heparin
170. Low-molecular-weight heparins
171. Low molecular weight heparin use during pregnancy: Issues of safety and practicality
172. Safety of low-molecular-weight heparin in pregnancy: A systematic review
173. Dose adjusted heparin treatment of deep Venous thrombosis: A comparison of unfractionated and low molecular weight heparin
174. Pharmacology of low molecular weight heparins
175. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin
176. Heparin-induced thrombocytopenia
177. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy
178. Low molecular weight heparin and ASA therapy in women with autoantibodies and unexplained recurrent fetal loss (U-RFL)
179. Bone density studies in pregnant women receiving heparin
180. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high-risk pregnancies
181. Long-term treatment of venous thromboembolic disease
182. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
183. The risks of antenatal subcutaneous heparin prophylaxis: A controlled trial
184. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk
185. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy
186. Prevention of venous thromboembolism in general surgical patients. Results of a meta-analysis
187. Collaborative overview of randomized trials of antiplatelet therapy III Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among medical and surgical patients
188. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) Trial
189. Place of aspirin in prophylaxis of venous thromboembolism
190. Thrombophilias and adverse outcomes of pregnancy - What should a clinician do?
191. Vascular-bed-specific hemostasis and hypercoagulable states
192. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies
193. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants
194. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?
195. Interaction of the protein C/protein S anticoagulant system, the endothelium and pregnancy
196. Prospective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study
197. The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion
198. Screening for heritable thrombophilic risk factors in a recurrent miscarriage population
199. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss
200. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss
201. A woman with five consecutive fetal deaths: Case report and retrospective analysis of hyperhomocysteinemia prevalence in 100 consecutive women with recurrent miscarriages
202. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss
203. Second-trimester pregnancy loss is associated with activated C resistance
204. Acquired activated protein C resistance and recurrent miscarriage - Prevalence and prospective outcome of untreated pregnancies
205. Factor V Leiden and factor II G20210A mutations in patients with recurrent abortion
206. Hemostatic and metabolic abnormalities in women with unexplained recurrent abortion
207. Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages
208. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses
209. Methylenetetrahydrofolate reductase (MTHFR) 677T to C mutation and unexplained early pregnancy loss
210. Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors
211. Polymorphism for mutation of cytosine to thymidine at location 677 in the methylenetetrahydrofolate reductase gene is associated with recurrent early fetal loss
212. Genetic risk factor for unexplained recurrent early pregnancy loss
213. Hyperhomocysteinemia: A risk factor in women with unexplained recurrent early pregnancy loss
214. Activated protein C resistance and factor V Leiden mutation can be associated with first- as well as second-trimester recurrent pregnancy loss
215. Factor V Leiden as a risk factor for miscarriage and reduced fertility
216. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure
217. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent - The Nimes Obstetricians and Haematologists Study5 (NOHA5)
218. Increased frequency of genetic thrombophilia in women with complications of pregnancy
219. Mutations in coagulation factors in women with unexplained late fetal loss
220. High prevalence of activated protein C resistance due to factor V Leiden mutation in cases of intrauterine fetal death
221. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause
222. Activated protein C resistance can be associated with recurrent fetal loss
223. Hyperhomocysteinemia and protein S deficiency in complicated pregnancies
224. Factor V Leiden and recurrent miscarriage - Prevalence and prospective pregnancy outcome
225. The Glasgow Outcome, APCR and Lipid (GOAL) pregnancy study: Significance of pregnancy associated activated protein C resistance
226. The risk of fetal loss in family members of probands with factor V Leiden mutation
227. Increased risk for fetal loss in carriers of the factor V Leiden mutation
228. Comparison of the risk of fetal loss between homozygous and heterozygous patients with factor V Leiden mutation
229. Pre-pregnancy thrombophilic abnormalities are associated with subsequent miscarriage
230. G20210A prothrombin gene mutation: Prevalence in a recurrent miscarriage population
231. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women
232. Pregnancy loss and thrombosis with protein C deficiency
233. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin
234. Resistance to activated protein C and the Leiden mutation: High prevalence in patients with abruptio placentae
235. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy
236. Hyperhomocysteinemia - A risk factor for abruptio placentae
237. Hyperhomocysteinemia: A risk factor for placental abruption or infarction
238. Underlying disorders associated with severe early-onset preeclampsia
239. Preeclampsia is associated with a reduced response to activated protein C
240. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia
241. The factor V Leiden mutation may predispose women to severe preeclampsia
242. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia
243. Severe preeclampsia and high frequency of genetic thrombophilic mutations
244. Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women
245. Maternal and neonatal outcome of preeclamptic pregnancies: The potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase
246. Prevalence of mutations in candidate genes for susceptibility to preeclampsia and HELLP syndrome in patients and female relatives - First results
247. Prevalence of the Leiden mutation in infants from pregnancies affected by severe preeclampsia
248. Preeclampsia and genetic risk factors for thrombosis: A case-control study
249. Maternal and fetal genetic thrombophilias are not associated with severe preeclampsia
250. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort
251. Hyperhomocysteinemia is significantly more common amongst South African women with preeclampsia
252. Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia
253. Elevated second-trimester serum homocyst(e)ine levels and subsequent risk of preeclampsia
254. Polymorphisms of methylenetetrahydrofolate reductase in women with pre-eclampsia
255. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia
256. 5, 10 Methylenetetrahydrofolate reductase polymorphism in black South African women with pre-eclampsia
257. The methylenetetrahydrofolate reductase C677T polymorphism is not associated with preeclampsia or the HELLP syndrome
258. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and preeclampsia in Japanese women
259. 677 C→T polymorphism of the methylenetetrahydrofolate reductase gene and preeclampsia
260. Hyperhomocysteinemia: A risk factor for preeclampsia?
261. Methylenetetrahydrofolate reductase 677 C→ polymorphism, plasma folate, vitamin B(12) concentrations, and risk of preeclampsia among black African women from Zimbabwe
262. Methylenetetrahydrofolate reductase 677 C→ polymorphism and plasma folate in relation to preeclampsia
263. Prothrombin G20210A mutation: Is it associated with preeclampsia
264. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia
265. The 4G/5G polymorphism of plasminogen activator inhibitor-I gene is associated with severe preeclampsia
266. Homocysteine levels in pregnancy induced hypertension (PIH), preeclampsia (PE), and intrauterine growth restriction (IUGR)
267. Intrauterine growth retardation, perinatal death, and maternal homocysteine levels
268. Placental genotyping of the factor V Leiden, prothrombin 20210A and the methylenetetrahydrofolate reductase (MTHFR) C677T alleles in IUGR pregnancies
269. Thromboprophylaxis in pregnancy reduces fetal losses in women with heritable thrombophilia: A prospective EPCOT study
270. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: A preliminary study
271. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene as a new risk factor for placental vasculopathy
272. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation